An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates
- PMID: 15845669
- DOI: 10.1213/01.ANE.0000149590.59294.3A
An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates
Abstract
We compared the adequacy of heparinization in neonates and older children undergoing cardiopulmonary bypass (CPB) by measuring heparin activity, thrombin formation, and thrombin activity. Ten neonates and 10 older children were administered 400 U/kg of heparin before CPB. Heparin anti-Xa activity, prothrombin fragment 1.2 (F1.2), and fibrinopeptide A (FPA) were measured at baseline, after 30 min on CPB, immediately post-CPB, and 3 and 24 h post-CPB. Heparin anti-Xa activity was significantly decreased during and immediately post-CPB in the neonatal group. F1.2 and FPA levels in neonates were significantly higher at baseline, decreased with the commencement of CPB, and increased to levels higher than those in older children after CPB. Our data show that with standard heparin doses, neonates exhibit less heparin anti-Xa activity during CPB. Higher baseline levels of F1.2 and FPA present in neonates indicate preoperative activation of their coagulation systems as compared with older children. Although F1.2 and FPA levels initially decrease with the commencement of CPB, probably representing hemodilution, the subsequent increase in these markers indicates significantly more thrombin formation and activity during and after CPB. These results raise the concern that 400 U/kg of heparin may not adequately suppress thrombin formation and activity in neonates undergoing CPB.
Similar articles
-
Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery.Thromb Res. 1996 Oct 1;84(1):45-54. doi: 10.1016/0049-3848(96)00160-0. Thromb Res. 1996. PMID: 8885146
-
Anticoagulation of children undergoing cardiopulmonary bypass is overestimated by current monitoring techniques.Arch Surg. 2000 Sep;135(9):1042-7. doi: 10.1001/archsurg.135.9.1042. Arch Surg. 2000. PMID: 10982508
-
Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.J Thorac Cardiovasc Surg. 2016 Feb;151(2):444-50. doi: 10.1016/j.jtcvs.2015.10.003. Epub 2015 Oct 9. J Thorac Cardiovasc Surg. 2016. PMID: 26553458
-
Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?J Cardiovasc Pharmacol. 1996;27 Suppl 1:S50-7. doi: 10.1097/00005344-199600001-00011. J Cardiovasc Pharmacol. 1996. PMID: 8938284 Review.
-
Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.J Cardiothorac Vasc Anesth. 1999 Aug;13(4 Suppl 1):18-29; discussion 36-7. J Cardiothorac Vasc Anesth. 1999. PMID: 10468245 Review.
Cited by
-
Use of Confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study.Pediatr Cardiol. 2014 Feb;35(2):208-14. doi: 10.1007/s00246-013-0760-y. Epub 2013 Jul 11. Pediatr Cardiol. 2014. PMID: 23843105 Clinical Trial.
-
Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients.Br J Clin Pharmacol. 2016 Jul;82(1):178-84. doi: 10.1111/bcp.12930. Epub 2016 May 2. Br J Clin Pharmacol. 2016. PMID: 26972703 Free PMC article.
-
Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery.J Extra Corpor Technol. 2010 Mar;42(1):9-19. J Extra Corpor Technol. 2010. PMID: 20437787 Free PMC article. Review.
-
[Explanation and interpretation of blood transfusion provisions for children undergoing cardiac surgery in the national health standard "Guideline for pediatric transfusion"].Zhongguo Dang Dai Er Ke Za Zhi. 2025 Jul 15;27(7):778-785. doi: 10.7499/j.issn.1008-8830.2503114. Zhongguo Dang Dai Er Ke Za Zhi. 2025. PMID: 40695508 Free PMC article. Chinese.
-
Perioperative Management of a Child with Hypoplastic Left Heart Syndrome of the Jehovah's Witness Faith Presenting for Hybrid Comprehensive Stage II Procedure.J Extra Corpor Technol. 2016 Sep;48(3):141-147. J Extra Corpor Technol. 2016. PMID: 27729708 Free PMC article.
References
-
- Dietrich W. Reducing thrombin formation during cardiopulmonary bypass: Is there a benefit of the additional anticoagulant action of aprotinin? J Cardiovasc Pharmacol 1996;27:S50–7.
-
- Slaughter TF, LeBleu TH, Douglas JM, et al. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994;80:520–6.
-
- Hirsh J. Mechanism of action and monitoring of anticoagulants. Semin Thromb Hemostas 1986;12:1–11.
-
- Hashimoto K, Yamagishi M, Sasaki T, et al. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1994;58:799–805.
-
- Lemmer JH, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002;123:213–7.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical